Please use this identifier to cite or link to this item:
|Title:||Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy|
|Citation:||Russell, F.M., Licciardi, P.V., Balloch, A., Biaukula, V., Tikoduadua, L., Carapetis, J.R., Nelson, J., Jenney, A.W.J., Waqatakirewa, L., Colquhoun, S., Cheung, Y.B., Tang, M.L.K., Mulholland, E.K. (2010-04-19). Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy. Vaccine 28 (18) : 3086-3094. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2010.02.065|
|Abstract:||Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p < 0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group. © 2010 Elsevier Ltd.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on May 27, 2018
WEB OF SCIENCETM
checked on Apr 16, 2018
checked on Apr 20, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.